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The first examples of arylphosphonium salts containing
a dicarba-closo-dodecaborane(12) (closo-carborane) are re-
ported; in contrast to the 1,12-carborane derivative, the 1,2-
and 1,7-isomers undergo a facile deboronation reaction in
polar solvents to afford the corresponding nido-carborane
phosphonium zwitterions.
Delocalised lipophilic cations (DLCs) can readily traverse
the lipophilic mitochondrial membrane and accumulate in
mitochondria.1–8 The selection of DLCs for use as tumour
imaging and anti-cancer agents has been based solely on their
advantageous physical properties, lipophilicity and delocalised
positive charge.2,8 A high negative electrical potential that exists
across the mitochondrial membrane enhances the uptake of
DLCs into the mitochondria.8 The potential difference across
the membrane in normal, healthy cells has been determined to
be −104 mV.9 Mitochondria from human colon carcinoma cells,
for example, have been shown to consistently exhibit elevated
membrane potentials of −163 mV, sufficient to account for a ten-
fold increase of DLC concentration in cancerous cells over healthy
cells.2
Phosphonium salts represent a promising class of DLCs for use
in tumour targeting and imaging. Tetraphenylphosphonium (TPP)
salts, triphenylmethylphosphonium (TPMP) salts and related
compounds based on these structures have demonstrated highly
cancer-selective accumulation and cytotoxicity.1,10–12 TPMP iodide,
radio-labelled with the 11C isotope, has been investigated for
in vitro uptake and retention in canine brain tumour in the interest
of imaging tumours using PET.13 Not only was this compound
rapidly taken up and retained in the tumour, but it was retained
for a significant time (ca. 95 min) and achieved a tumour : healthy
tissue ratio of 48 : 1. This ratio is also one order of magnitude
greater than for other available glioma PET tracers and for
clinical agents currently used in boron neutron capture therapy
(BNCT).13–16 TPMP is also known to suppress tumour growth.17
Furthermore, animal studies have demonstrated that the expected
toxic effects of TPMP may not prevent its use in humans.13 In
the context of BNCT, incorporation of boron into this compound
would potentially result in the selective delivery of boron to the
tumour site.
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Compounds that are selective toward certain cancers by target-
ing the mitochondria represent a new class of BNCT agents. To
our knowledge, the only example of a carborane-containing DLC
reported to date is the 1,12-carborane analogue of dequalinium,
which was found to accumulate selectively in human epidermoid
carcinoma of the oral cavity and rat glioma in vitro.1 It also
exhibited similar uptake and retention properties to Rhodamine
123,MKT-077 andTPP chloride, suggesting this and other boron-
containing DLCs such as the phosphonium salts are worthy
of investigation as potential BNCT agents. Herein we describe
the synthesis and characterisation of novel carborane-containing
phosphonium derivatives. The present study describes TPMP
analogues that have one phenyl group replaced by either a
closo-1,2-, 1,7- or 1,12-carborane. In two out of three cases,
a deboronation reaction occurs in polar solvents to afford the
corresponding nido-carborane phosphonium zwitterions.
Syntheses of trisubstituted phosphines from the parent closo-
carboranes were based upon the known preparation of the closo-
1,2-carborane derivative 1.18 One equivalent of n-BuLi was treated
with closo-1,2-, 1,7- or 1,12-carborane in DME at low temper-
atures to minimise disproportionation and hence disubstitution
at the carbon atoms,19 and chlorodiphenylphosphine was then
added to afford the desired phosphine compounds 1–3.18,20–22
Small amounts of the disubstituted carborane derivative were
also obtained in all three cases and could be separated readily
from the monosubstituted species by means of flash column
chromatography.
The synthesis of the phosphonium salts was achieved in all cases
by a facile methylation reaction between 1–3 and MeI to afford
the corresponding phosphonium iodides 4–6 (Schemes 1–3). An
excess ofMeIwas used in the reaction as this stepwas generally not
high-yielding, possibly because the carborane cage is somewhat
electron-withdrawing thereby deactivating the phosphorus centre
toward electrophiles. The characterisation of 4–6 was primarily
achieved bymeans ofmass spectrometry andNMRspectroscopy.‡
The Me group exhibited a downfield-shifted doublet in the
1H NMR spectra, with 2JPH = 13–14 Hz. A single peak in the
31P{1H} NMR spectra at d 24–30 was located downfield from
the peak of the corresponding tertiary phosphine precursor.
Compounds 5 and 6 were found to readily deboronate to afford
the corresponding nido-carborane zwitterions 7 and 8, respectively,
in polar solvents such as DMSO and DMF. Alternatively,
treatment of 5, for example, with fluoride ion in EtOH solution
resulted in the rapid formation of the zwitterionic product 7 with
an optimised yield (Scheme 1).‡23 The deboronation reaction was
not observed for 4, which contains closo-1,12-carborane and is
therefore highly resistant to the deboronation reaction because
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Scheme 1 Reagents: (i) MeI; (ii) CsF, EtOH.
Scheme 2 Reagents: (i) MeI; (ii) CsF, EtOH.
Scheme 3 Reagent: (i) MeI.
no boron atoms within the cluster are bonded to two adjacent
and electronegative carbon atoms.24 In contrast, the deboronation
of closo-1,2-carborane under mild, non-basic conditions is known
with alcohols,water and acids25–27 andhas also beenobservedwhen
functional groups located a to the cage are electron-withdrawing
and the compounds are exposed to polar solvents containing small
amounts of H2O or MeOH.28,29 In our case, the deboronation
reactions occur in polar solutions such as dry DMF and thus
most likely proceed by nucleophilic attack of the iodide counter-
ion on the most electrophilic boron atoms in the cage, i.e. B3 (or
B6) for 1,2-carborane and B2 (or B3) for 1,7-carborane. To our
knowledge, no other halides except fluoride23,29–31 are known to
deboronate closo-1,2- and 1,7-carborane.§
Selective degradation of the closo-carborane cages in 5 and 6 to
the corresponding nido derivatives was confirmed by the presence
of an upfield broad peak at d −2 in the 1H{11B} NMR spectra
of 7 and 8 which is attributed to the bridging H-atom, as well as
the significant upfield shifts of resonances in the 11B{1H} NMR
spectra. In addition to the NMR studies, the structure of 7 was
confirmed byX-ray crystallography.¶AnORTEP32 representation
of 7 is presented in Fig. 1. The bond angles and lengths fall in the
range of typical alkyltriarylphosphonium salts, e.g. MePh3P+X−
(X = ClO4, BF4),33 and are almost identical to those found in
the phosphonium saltMePh3P+(7,8-Et2-7,8-nido-C2B9H10)−.34 The
central phosphorus atom is close to an ideal tetrahedral geometry
with bond angles ranging from 112.87(6)◦ (C(2)–P(1)–C(4)) to
106.88(6)◦ (C(2)–P(1)–C(10)). The C(2)–P(1) bond length of 7
(1.7867(14) A˚) is only marginally shorter than the C(10)–P(1)
and C(4)–P(1) bond lengths (1.7982(13) and 1.7981(13) A˚, respec-
tively) indicating there is very little double-bond character between
the phosphorus centre and the cage carbon atom.34–36 Hence, a
zwitterionic structure bearing separate but delocalised positive
and negative charges at the MePh2P moiety and nido-carborane
cage, respectively, is consistent with the X-ray data rather than
a ylide-like structure in which there exists significant double-
bond character and, consequently, a shortened phosphorus–
carbon bond.* Such bond shortening has been observed in simple
phosphorus ylide compounds, e.g. PPh3CH2 (1.661 A˚)37 and
phosphorus–borane ylides such as endo-7-[Ph2(H)P]-8-R-hypho-
7,8-C2B6H11, in which the P–C bond lengths were found to be
1.737(3) and 1.742(3) A˚ for R = H and Me, respectively.38
This journal is © The Royal Society of Chemistry 2007 Dalton Trans., 2007, 1982–1985 | 1983
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Fig. 1 An ORTEP representation and atomic numbering scheme
of compound 7 shown with 50% probability ellipsoids. Selected
bond distances (A˚): C(1)–C(2) = 1.5680(17), C(2)–P(1) = 1.7867(14),
C(3)–P(1) = 1.7957(14), C(4)–P(1)= 1.7981(13), C(10)–P(1)= 1.7982(13).
Selected bond angles (◦): C(1)–C(2)–P(1) = 116.46(9), C(5)–C(4)–P(1) =
120.96(10), C(9)–C(4)–P(1) = 119.20(10), C(15)–C(10)–P(1) = 119.80(10),
C(11)–C(10)–P(1) = 120.64(10), C(2)–P(1)–C(3) = 109.76(6), C(2)–P(1)–
C(4) = 112.87(6), C(3)–P(1)–C(4) = 108.23(6), C(2)–P(1)–C(10) =
106.88(6), C(3)–P(1)–C(10) = 109.27(6), C(4)–P(1)–C(10) = 109.79(6).
In conclusion, we have reported the first examples of arylphos-
phonium salts containing a closo-carborane. In contrast to the
1,12-carborane derivative 4, the 1,2- and 1,7-isomers undergo
a facile deboronation reaction in polar solvents to afford the
corresponding zwitterionic nido-carborane phosphonium species.
Preliminary in vitro cytotoxicity screening of 4 against the SF268
(human glioblastoma) cell line demonstrated a favourable GI50 >
40 lM compared with the control compound TPMP (GI50 =
12.5 lM). We are currently evaluating the detailed tumour cell
uptake and biodistribution of 4 and the zwitterionic species 7 and
8, and the results of this study will be published in due course.
We thankDr IanLuck (TheUniversity of Sydney) for assistance
with the NMR studies and Dr Carleen Cullinane (Peter MacCal-
lum Cancer Institute, Melbourne) for the cytotoxicity studies. We
also thank the Australian Research Council for financial support.
Notes and references
‡NMR spectroscopic and ESI-MS data for 4: 1HNMR (d6-DMSO) d 8.11
(m, 4H), 7.95 (m, 2H), 7.80 (m, 4H), 4.33 (br s, 1H, Ccage-H), 3.04 (d, 2JP,H =
13.42 Hz, 3H). 11B{1H} NMR (d6-acetone) d −12.5 (br, 10B). 31P{1H}
NMR (d6-DMSO) d 27.1 (s). 13C{1H} NMR (d6-DMSO) d 135.96 (s, Ph),
133.81 (d, JP,C = 10.36 Hz, Ph), 129.98 (d, JP,C = 12.98 Hz, Ph), 116.22
(d, JP,C = 87.95 Hz, Ph), 70.48 (s, CcageH), 6.90 (d, JP,C = 56.05 Hz), CcageP
not observed.MS:m/z 343.4 (M+). NMR spectroscopic and ESI-MS data
for 5: 1H NMR (d6-acetone) d 8.46 (m, 6H, Ph), 8.10 (m, 4H, Ph), 5.70
(br s, 1H, Ccage-H), 3.64 (d, 2JP,H = 13.12 Hz, 3H, CH3). 11B{1H} NMR
(d6-acetone) d −6.1 (br, 3B), −7.9 (br, 3B), −10.0 (br, 1B), −11.4 (br,
3B). 31P{1H} NMR (d6-acetone) d 30.0 (s). MS: m/z 344.3 (M+). NMR
spectroscopic and ESI-MS data for 6: 1H NMR (d6-DMSO) d 8.23 (m,
4H), 7.98 (m, 2H), 7.84 (m, 4H), 4.52 (br s, 1H, Ccage-H), 3.23 (d, 2JP,H =
13.49 Hz, 3H). 11B{1H} NMR (d6-acetone) d −1.3 (br, 1B), −3.4 (br, 1B),
−7.8 (br, 3B), −10.0 (br, 3B), −13.4 (br, 2B). 31P{1H} NMR (d6-acetone)
d 26.4 (s). MS: m/z 343.5 (M+). NMR spectroscopic data for 7: 1H NMR
(d7-DMF) d 7.91–7.76 (m, 10H, Ph), 3.48 (s, 1H, Ccage-H), 2.68 (d, 2JP,H =
13.61, 3H, CH3). 11B{1H} NMR (d6-acetone) d −10.0 (br, 2B), −11.4 (br,
1B), −13.8 (br, 1B), −14.9 (br, 1B), −16.2 (br, 1B), −20.7 (br, 1B), −29.0
(br, 1B), −33.9 (br, 1B). 31P{1H} NMR (d7-DMF) d 29.9 (s). 13C{1H}
NMR (d7-DMF) d 129.36 (s, Ph), 128.19 (d, JP,C = 10.06 Hz, Ph), 128.05
(d, JP,C = 10.06 Hz, Ph), 124.61 (d, JP,C = 12.07 Hz, Ph), 118.11 (d, JP,C =
92.16 Hz, Ph), 117.16 (d, JP,C = 86.93 Hz, Ph), 3.19 (d, JP,C = 57.94 Hz,
CH3), CcageH and CcageP were not observed.
§ Interestingly, the deboronation reaction is not reported for boron-
substituted alkylphosphonium bromide salts of closo-1,2-carborane in
which the cationic centre is separated from the carborane cage by at least
four bonds.39
¶Colourless prismatic crystals were grown from the slow diffusion of
diethyl ether into a DMF solution containing 7 over several days. X-
Ray data: Formula C15H24B9P, M 332.60, monoclinic, space group P21/c
(#14), a = 11.4316(14), b = 9.4232(10), c = 17.547(2) A˚, b = 102.805(6)◦,
V = 1843.2(4) A˚3, Dc = 1.199 g cm−3, Z = 4, crystal size = 0.314 ×
0.290 × 0.157 mm, colourless prism, temperature = 150(2) K, k(MoKa) =
0.71073 A˚, l(MoKa) = 0.143 mm−1, T(SADABS)min,max = 0.750, 0.98,
2hmax = 61.28, hkl range = −16 to 16, −13 to 13, −25 to 25, N =
37976, N ind = 5637 (Rmerge 0.0635), Nobs = 4587 (I > 2r(I)), Nvar = 242,
residualsR1=∑‖F o|− |F c‖/
∑
|F o| forF o> 2r(F o);wR2= (
∑
w(F o2 −
F c2)2/
∑
(wF c2)2)1/2 all reflections w = 1/[r2(F o2) + (0.0632P)2 + 0.8298P],
where P = (F o2 + 2F c2)/3.R1(F) = 0.0444, wR2(F 2) = 0.1318, GoF(all) =
1.085, Dqmin,max = −0.584, 0.499 e A˚−3. CCDC reference number 629314.
For crystallographic data in CIF or other electronic format see DOI:
10.1039/b700689f
* The X-ray structure of 7 also reveals a number of ring-stacking inter-
actions present throughout the crystal lattice. The zwitterionic molecules
pack together forming infinite one-dimensional chains through offset face-
to-face interactions which are illustrated by C(7) · · ·C(12) [at (x, 1/2 − y,
1/2 + z)] = 3.446(2) A˚. These chains pack closely together with adjacent
chains forming a two-dimensional sheet-like motif, which propagates in
the bc-plane and is held together by p–BH interactions between the
delocalised carborane cages and the phenyl rings of adjacent molecules.
Indicative BH · · · ring centroid distances are the B(5)H · · · ring centroid
of the C(12)-containing ring = 3.25 A˚ and B(4)H · · · ring centroid of the
C(8)-containing ring = 3.41 A˚.
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